Biomarkers in cancer staging, prognosis and treatment selection

Joseph A. Ludwig; John N. Weinstein

doi:10.1038/nrc1739

Biomarkers in cancer staging, prognosis and treatment selection

Joseph A. Ludwig, John N. Weinstein

Research output: Contribution to journal › Review article › peer-review

1397 Scopus citations

Abstract

Advances in genomics, proteomics and molecular pathology have generated many candidate biomarkers with potential clinical value. Their use for cancer staging and personalization of therapy at the time of diagnosis could improve patient care. However, translation from bench to bedside outside of the research setting has proved more difficult than might have been expected. Understanding how and when biomarkers can be integrated into clinical care is crucial if we want to translate the promise into reality.

Original language	English (US)
Pages (from-to)	845-856
Number of pages	12
Journal	Nature Reviews Cancer
Volume	5
Issue number	11
DOIs	https://doi.org/10.1038/nrc1739
State	Published - Nov 2005
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1038/nrc1739

Cite this

@article{7606e9b62a7a411cb2b4ede4dfa32a74,

title = "Biomarkers in cancer staging, prognosis and treatment selection",

abstract = "Advances in genomics, proteomics and molecular pathology have generated many candidate biomarkers with potential clinical value. Their use for cancer staging and personalization of therapy at the time of diagnosis could improve patient care. However, translation from bench to bedside outside of the research setting has proved more difficult than might have been expected. Understanding how and when biomarkers can be integrated into clinical care is crucial if we want to translate the promise into reality.",

author = "Ludwig, {Joseph A.} and Weinstein, {John N.}",

note = "Funding Information: We thank Maria Chan (FDA) for guidance regarding Table 1 and Anna Maria Calcagno (NCI) for her constructive scientific input. This work was supported by the Intramural Research Program of the NIH, the National Cancer Institute and the Center for Cancer Research. We are grateful to Anna Barker and the reviewers whose constructive comments and suggestions significantly improved the manuscript.",

year = "2005",

month = nov,

doi = "10.1038/nrc1739",

language = "English (US)",

volume = "5",

pages = "845--856",

journal = "Nature Reviews Cancer",

issn = "1474-175X",

publisher = "Nature Publishing Group",

number = "11",

}

TY - JOUR

T1 - Biomarkers in cancer staging, prognosis and treatment selection

AU - Ludwig, Joseph A.

AU - Weinstein, John N.

N1 - Funding Information: We thank Maria Chan (FDA) for guidance regarding Table 1 and Anna Maria Calcagno (NCI) for her constructive scientific input. This work was supported by the Intramural Research Program of the NIH, the National Cancer Institute and the Center for Cancer Research. We are grateful to Anna Barker and the reviewers whose constructive comments and suggestions significantly improved the manuscript.

PY - 2005/11

Y1 - 2005/11

N2 - Advances in genomics, proteomics and molecular pathology have generated many candidate biomarkers with potential clinical value. Their use for cancer staging and personalization of therapy at the time of diagnosis could improve patient care. However, translation from bench to bedside outside of the research setting has proved more difficult than might have been expected. Understanding how and when biomarkers can be integrated into clinical care is crucial if we want to translate the promise into reality.

AB - Advances in genomics, proteomics and molecular pathology have generated many candidate biomarkers with potential clinical value. Their use for cancer staging and personalization of therapy at the time of diagnosis could improve patient care. However, translation from bench to bedside outside of the research setting has proved more difficult than might have been expected. Understanding how and when biomarkers can be integrated into clinical care is crucial if we want to translate the promise into reality.

UR - http://www.scopus.com/inward/record.url?scp=28544446695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28544446695&partnerID=8YFLogxK

U2 - 10.1038/nrc1739

DO - 10.1038/nrc1739

M3 - Review article

C2 - 16239904

AN - SCOPUS:28544446695

SN - 1474-175X

VL - 5

SP - 845

EP - 856

JO - Nature Reviews Cancer

JF - Nature Reviews Cancer

IS - 11

ER -

Biomarkers in cancer staging, prognosis and treatment selection

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this